The main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are:
* How effective is PJ009 in treating short bowel syndrome? * Is PJ009 safe in these patients? Researchers will compare PJ009 to a placebo (a look-alike substance that contains no drug) to see if PJ009 works to treat SBS.
Participants will
* Receive daily subcutaneous injections of PJ009 or placebo according to weight for 24 weeks, and then the participants receive placebo will be switched to receive PJ009 for another 12 weeks, while participants receive PJ009 continued the same treatment until the end of 36 weeks, * Visit the clinic at the end of week 1(w1), w2, w4, w8, w12, w16, w20, w24, w30 and w36 for assessment, * Keep a diary of the amount of their parenteral nutrition/ intravenous fluids (PN/IV), enteral nutrition and urine volume.
Male and female aged ≥ 14 years;
SBS patients dependent on PN/IV support for at least 6 consecutive months due to major intestinal resection;
At least 3 PN/IV support sessions per week are required 1 week before screening or 2 weeks before baseline;
Be on stable PN/IV support for at least 4 consecutive weeks before administration;
Have used teduglutide in the past or may be allergic to teduglutide or its components;
Have used natural GLP-2 or its analogs, human growth hormone or its analogs within 6 months before screening;
Have used glutamine, octreotide, GLP-1 analogs or dipeptidyl peptidase-IV inhibitors within 30 days before screening;
With active Crohn's disease or those who need to change biological therapy within 6 months before screening;